High drug prices have become a significant issue in the United States, a symptom of a patent system that often serves entrenched interests rather than promoting innovation and improving social welfare. The problem is particularly acute in the pharmaceutical sector, where patent strategies, like those employed by AbbVie with Humira, hinder competition and maintain market […]
Tag: AbbVie
Revolutionizing Cancer Therapy: ASCO 2025 Highlights
Antibody Drug Conjugates (ADCs) have been a game-changer in precision oncology over the past 25 years. Originally a bold concept, ADCs have now become a cornerstone in treating both blood cancers and solid tumors. The latest generation of ADCs features advanced technologies like smarter linkers, novel payloads, and higher drug-antibody ratios, pushing the boundaries of […]
Growing Pharma Tuck-In Deals Post-Mediocre Small Biotech Q1
Following a lackluster first quarter for small biotechs, the pharmaceutical industry is witnessing a surge in tuck-in deals. Ventyx, with upcoming Phase II Parkinson’s disease results, struck a deal with Sanofi granting the pharma right of first negotiation (ROFN) on an acquisition. This agreement, driven by a shared interest in novel central nervous system therapies, […]
